Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.?(Nasdaq: VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.

Click to view original post